Hemcheck Sweden AB has signed a 3-month evaluation agreement with potential continuation into a 36-month long distribution agreement with Sanova Pharma GesmbH (”Sanova”), regarding the Austrian market. Sanova is a subsidiary to Herba Chemosan Group which in turn is a subsidiary of McKesson. Sanova is a leading distributor of medical equipment and pharmaceuticals in Austria. The agreement is formed to evaluate the collaboration and the market potential.
– Sanova is well established in the Austrian market with a relevant product portfolio and customer base. They have strong backing and a willingness to invest in novelties. We look forward to working with Sanova in Austria and hope for a successful collaboration, says Joen Averstad, CEO of Hemcheck.
– We are happy to start this collaboration and evaluation together with Hemcheck, since we believe there is good potential for the products in the Austrian market. We have already informed our sales team and we look forward to starting customer discussions, says Harald Deutsch, Division Manager Medical Systems at Sanova.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
About Sanova Pharma GesmbH
Sanova is an Austrian company with its headquarters in Vienna, an operating facility in Gallspach / Upper Austria and subsidiaries in the Czech Republic and Switzerland. Sanova is a company with a history of over 75 years in the health sector, and currently employs over 200 people. Sanova has 3 main areas of business: pharmaceuticals, medical systems and logistics. Sanova is part of Herba Chemosan Group which in turn is a subsidiary of McKesson, a global healthcare distributor.
Read more at: https://sanova.at/en/medical-systems/about-medical-systems/
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.